Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial
RCT (n=181) found that among patients with heart failure with preserved ejection fraction, praliciguat, a soluble guanylate cyclase stimulator, did not significantly improve peak V̇o2 from baseline to week 12 vs placebo.
Source:
Journal of the American Medical Association
Resource links:
SPS commentary:
A separate study found that vericiguat another soluble guanylate cyclase stimulator did not improve outcomes in this group of patients vs placebo.
A related editorial discusses the implications of these studies. It concludes that overall, the results of these 2 randomised clinical trials of soluble guanylate cyclase stimulators in patients with heart failure with preserved ejection fraction (HFpEF) suggest that targeting this pathway is not an effective population-based strategy to improve physical functioning for patients with HFpEF in the short term. However, due to the approaches for patient selection, the length of follow-up, and the end points chosen, these studies do not negate the potential that these agents may have to improve outcomes. Future studies should select patients with HFpEF based on demonstrable endothelial dysfunction, and patients should be followed up longer for an end point such as a reduction in HF hospitalisation.